A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
- Schwarze, J. K. (Speaker)
- Vanbinst, A. (Contributor)
Activiteit: Talk or presentation at a conference